“Discontinuation Rate of Dual Antiretroviral Therapy With Dolutegravir Plus Lamivudine in People Living With HIV: A Systematic Review”. 2022. Research, Society and Development 11 (12): e430111234758. https://doi.org/10.33448/rsd-v11i12.34758.